Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: Study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA)

BMC Geriatrics

Volumn 9, Issue 1, 2009, Pages

  Chernyak, Nadja ^a   Petrak, Frank ^b   Plack, Kristin ^c   Hautzinger, Martin ^d   Müller, Matthias J ^e   Giani, Guido ^a   Icks, Andrea ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e Clinic for Psychiatry and Psychotherapy   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

AGED; ARTICLE; BLOOD SAMPLING; COGNITIVE THERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; GERIATRIC DISORDER; GLYCEMIC CONTROL; GROUP THERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TIME; BIOASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEPRESSION; ECONOMICS; EVALUATION; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; EVALUATION STUDIES AS TOPIC; HUMANS; TREATMENT OUTCOME;

EID: 68349119025     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-9-25     Document Type: Article

References (49)

1. Economic evidence in affective disorders: a review. M Löthgren, Eur J Health Econ 2004 5 suppl 1 12 19 10.1007/s10198-005-0283-4 (Pubitemid 39440392)
2. Cost-of-illness studies of depression. A systematic review. M Luppa S Heinrich MC Angermeyer HH König SG Riedel-Heller, J Affect Disord 2007 98 29 43 10.1016/j.jad.2006.07.017 16952399 (Pubitemid 46048916)
3. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. S Ali MA Stone JL Peters MJ Davies K Khunti, Diabet Med 2006 23 1165 73 10.1111/j.1464-5491.2006.01943.x 17054590 (Pubitemid 44600576)
4. The prevalence of co-morbid depression in adults with diabetes: a meta-analysis. RJ Anderson KE Freedland RE Clouse PJ Lustman, Diabetes Care 2001 24 1069 1078 10.2337/diacare.24.6.1069 11375373
5. Affective and anxiety disorders in a German sample of diabetic patients: prevalence, comorbidity and risk factors. N Hermanns B Kulzer M Krichbaum T Kubiak T Haak, Diabet Med 2005 22 293 300 10.1111/j.1464-5491.2005.01414.x 15717877 (Pubitemid 40313856)
6. Relationship of depression and diabetes self-care, medication adherence, and preventive care. EH Lin W Katon M Von Korff C Rutter GE Simon M Oliver P Ciechanowski EJ Ludman T Bush B Young, Diabetes Care 2004 27 2154 2160 10.2337/diacare.27.9.2154 15333477 (Pubitemid 39167178)
7. Depression and diabetes: Impact of depressive symptoms on adherence, function and costs. P Ciechanowski W Katon J Russo, Arch Int Med 2000 160 3278 3285 10.1001/archinte.160.21.3278
8. Cardiac risk factors in patients with diabetes mellitus and major depression. WJ Katon EH Lin J Russo M Von Korff P Ciechanowski G Simon E Ludman T Bush B Young, J Gen Intern Med 2004 19 1192 1199 15610329 10.1111/j.1525-1497. 2004.30405.x (Pubitemid 40041383)
9. Potentially modifiable factors associated with disability among people with diabetes. M Von Korff W Katon EH Lin G Simon E Ludman M Oliver P Ciechanowski C Rutter T Bush, Psychosom Med 2005 67 233 240 10.1097/01.psy. 0000155662.82621.50 15784788 (Pubitemid 40410958)
10. Depression and poor glycemic control. PJ Lustman RJ Anderson KE Freedland M de Groot, Diabetes Care 2000 23 934 942 10.2337/diacare.23.7.934 10895843
11. Association of depression and diabetes complications: A meta-analysis. M De Groot RJ Anderson KE Freedland RE Clouse PJ Lustman, Psychosom Med 2001 63 619 630 11485116
12. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. SA Black KS Markides LA Ray, Diabetes Care 2003 26 2822 2828 10.2337/diacare.26.10.2822 14514586 (Pubitemid 37205553)
13. Diabetes, depression, and quality of life: a population study. RD Goldney PJ Phillips LJ Fisher DH Wilson, Diabetes Care 2004 27 1066 1070 10.2337/diacare.27.5.1066 15111522 (Pubitemid 38579767)
14. Depressive symptoms and mortality among persons with and without diabetes. X Zhang SL Norris EW Gregg YJ Cheng G Beckles HS Kahn, Am J Epidemiol 2005 161 652 660 10.1093/aje/kwi089 15781954 (Pubitemid 40411093)
15. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. W Katon CR Cantrell MC Sokol E Chiao JM Gdovin, Arch Intern Med 2005 165 2497 2503 10.1001/archinte.165.21.2497 16314547 (Pubitemid 41720012)
16. Prevalence and costs of major depression among elderly claimants with diabetes. E Finkelstein J Bray H Chen M Larson, Diabetes Care 2003 26 415 420 10.2337/diacare.26.2.415 12547872 (Pubitemid 36929065)
17. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. LE Egede D Zheng K Simpson, Diabetes Care 2002 25 464 470 10.2337/diacare.25.3.464 11874931 (Pubitemid 41103337)
18. Diabetes complications and depression as predictors of health care costs. G Simon W Katon E Lin E Ludman M Von Korff P Ciechanowski B Young, Gen Hosp Psychiatry 2005 27 344 351 10.1016/j.genhosppsych.2005.04.008 16168795 (Pubitemid 41317050)
19. Depressive symptoms and the cost of health services in HMO patients age 65 and over: a four-year prospective study. J Unützer DL Patrick G Simon D Grembowski E Walker C Rutter W Katon, JAMA 1997 277 1618 1623 10.1001/jama.277.20.1618 9168292
20. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. W Katon J Unutzer M Fan JJ Williams M Schoenbaum E Lin EM Hunkeler, Diabetes Care 2006 29 265 270 10.2337/diacare.29.02.06.dc05-1572 16443871
21. The PHQ-9: validity of a brief depression severity measure. K Kroenke RL Spitzer JB Williams, J Gen Intern Med 2001 16 606 13 11556941 10.1046/j.1525-1497.2001.016009606.x (Pubitemid 32823891)
22. HU Wittchen M Zaudig T Fydrich, SKID. Strukturiertes Klinisches Interview für DSM-IV Göttingen: Hogrefe 1997
23. Cost-effectiveness in health and medicine. MR Gold JB Seigel L Russell MC Weinstein, New York: Oxford University Press 1996
24. Methods for the Economic Evaluation of Health Care Programmes. MF Drummond MJ Sculpher GW Torrance B O'Brien GL Stoddart, Oxford: Oxford University Press 2005
25. Modeling valuations for EuroQol health states. P Dolan, Med Care 1997 35 1095 1108 10.1097/00005650-199711000-00002 9366889
26. The estimation of a preference-based measure of health from the SF-36. J Brazier J Roberts M Deverill, J Health Econ 2002 21 271 92 10.1016/S0167- 6296(01)00130-8 11939242 (Pubitemid 34143147)
27. EQ-5D value sets: Inventory, comparative review and user guide. A Szende M Oppe N Devlin, Dordrecht: Springer 2007
28. Validating the EQ-5D with time trade off for the German population. W Greiner C Claes JJ Busschbach JM Graf von der Schulenburg, Eur J Health Econ 2005 6 124 130 10.1007/s10198-004-0264-z (Pubitemid 40905009)
29. Deriving a preference-based single index from the UK SF-36 Health Survey. J Brazier T Usherwood R Harper K Thomas, J Clin Epidemiol 1998 51 1115 28 10.1016/S0895-4356(98)00103-6 9817129 (Pubitemid 28527167)
30. The estimation of a preference-based measure of health from the SF-36. J Brazier J Roberts M Deverill, J Health Econ 2002 21 271 92 10.1016/S0167- 6296(01)00130-8 11939242 (Pubitemid 34143147)
31. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. A Manca N Hawkins M Sculpher, Health Econ 2005 14 487 96 10.1002/hec.944 15497198 (Pubitemid 40723857)
32. Methods to analyse cost data of patients who withdraw in a clinical trial setting. JB Oostenbrink MJ Al MP Rutten-van Molken, Pharmacoeconomics 2003 21 1103 1112 10.2165/00019053-200321150-00004 14596629 (Pubitemid 37330551)
33. The analysis of incomplete cost data due to dropout. JB Oostenbrink MJ Al, Health Econ 2005 14 763 776 10.1002/hec.966 15729743 (Pubitemid 41093974)
34. A multiple imputation strategy for clinical trials with truncation of patient data. P Lavori R Dawson D Shera, Stat Med 1995 14 1913 1925 10.1002/sim.4780141707 8532984
35. Multiple imputation after 18+ years. DB Rubin, J Am Stat Assoc 1996 91 473 489 10.2307/2291635
36. Multiple imputation in healthcare databases: an overview and some applications. DB Rubin N Schenker, Stat Med 1991 10 595 598 10.1002/sim. 4780100410
37. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. AH Briggs DE Wonderling CZ Mooney, Health Econ 1997 6 327 340 10.1002/(SICI)1099-1050(199707) 6:4<327::AID-HEC2823.0.CO;2-W 9285227
38. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. MG Hunink JR Bult J de Vries MC Weinstein, Med Decis Making 1998 18 337 346 10.1177/0272989X9801800312 9679999 (Pubitemid 28307565)
39. The CE plane: a graphic representation of cost-effectiveness. WC Black, Med Decis Making 1990 10 212 14 10.1177/0272989X9001000308 2115096
40. Costs, effects and C/E-ratios alongside a clinical trial. BA Van Hout MJ Al GS Gordon FF Rutten, Health Econ 1994 3 309 19 10.1002/hec.4730030505 7827647
41. Cost-effectiveness acceptability curves facts, fallacies and frequently asked questions. E Fenwick BJ O'Brien A Briggs, Health Econ 2004 13 405 415 10.1002/hec.903 15127421 (Pubitemid 38660390)
42. Representing uncertainty: the role of cost-effectiveness acceptability curves. E Fenwick K Claxton M Sculpher, Health Econ 2001 10 779 787 10.1002/hec.635 11747057 (Pubitemid 34041389)
43. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. S Ramsey R Willke A Briggs R Brown M Buxton A Chawla J Cook H Glick B Liljas D Petitti S Reed, Value Health 2005 8 521 33 10.1111/j.1524-4733.2005.00045.x 16176491 (Pubitemid 41727304)
44. Assessing the costs of healthcare technologies in clinical trials. K Johnston MJ Buxton DR Jones R Fitzpatrick, Health Technol Assess 1999 3 6 1 76 10350450
45. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses. D Wonderling S Langham M Buxton C Normand C McDermott, BMJ 1996 312 1274 8 8634618
46. Self-reports of health-care utilization: Diary or questionnaire? M Van den Brink WB van den Hout AM Stiggelbout HP Cornelis JH van de Velde J Kievit, Int J Technol Assess Health Care 2005 21 298 304 16110708
47. Cost measurement in economic evaluations of health care: whom to ask? M Van den Brink WB van den Hout AM Stiggelbout CJ van de Velde J Kievit, Med Care 2004 42 740 746 10.1097/01.mlr.0000132351.78009.a1 15258475
48. The missing link: on the line between C and E. WBF Brouwer FFH Rutten, Health Econ 2003 12 629 636 10.1002/hec.764 12898661 (Pubitemid 37038359)
49. Patient and informal caregiver time in cost-effectiveness analysis. A response to recommendations of the US Panel. WBF Brouwer MA Koopmanschap FFH Rutten, Intl J Technol Assess Health Care 1998 14 505 513 10.1017/ S026646230001148X